Bio-medical veteran joins F2G as CEO
F2G Ltd, the Eccles-based anti-fungal drug discovery and development company, has appointed Ian Nicholson as its chief executive.
Mr Nicholson has more than 25 years’ experience in management and transactions within the life sciences sector. He is currently, and will remain, an operating partner of London-based Advent Life Sciences.
Advent was one of two new investors which backed F2G in a $30m fundraising last September. The deal co-incided with the departure of chief executive Shane Kelly.
Dr Richard White, executive chairman of F2G, commented, “We are delighted to welcome such an experienced executive to lead the company, and I look forward to working closely with him.”
Dr White will now revert to his former role of non-executive Chairman.
Mr Nicholson added, “I am excited to join F2G at this critical stage and lead the company in the successful development of an important first-in-class drug to treat Aspergillosis, an area of high unmet medical need.”
His track record in the sector includes eight years as chief executive of oncology R&D company, Chroma Therapeutics. Before that he was senior vice president for business development at biotech company Celltech Group.
